News Related to Satralizumab

Related coverage linked through entity extraction aliases.

Neuromyelitis Optica Spectrum Disorder Pipeline Shows 10+ Active Therapies in Development

Mar 05, 2026

Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.

Clinical Trials Embrace AI, Real-World Data Integration, and Digital Protocol Transformation

Feb 25, 2026

Industry leaders highlight advances in AI-enabled trial monitoring, real-world data interoperability, and protocol-driven eSource systems, while emphasizing the need for community engagement in diversity efforts and addressing operational risks in rare disease trials.